FULC vs SION
FULC: Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on unlocking gene expression to treat serious, rare genetic diseases. SION: A clinical-stage biotech pioneering the first drugs to directly stabilize CFTR's NBD1 domain, tackling the "undruggable" target in cystic fibrosis.
Side-by-side fundamentals
| Metric | FULC | SION | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $3.58 | $47.13 | |
| Market cap as of 2026-08-03 | $273M | $2.1B | |
| PEG as of 2026-08-03 | n/a | -0.89 | |
| Net margin as of 2026-08-03 | +8.1% | n/a | |
| Operating margin as of 2026-08-03 | -3.6% | n/a | |
| ROE as of 2026-08-03 | -22.5% | -27.3% | FULC higher |
| ROA as of 2026-08-03 | -21.2% | -25.9% | FULC higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.00 | Tie |
| Beta as of 2026-08-03 | 1.34 | 0.91 | |
| 1-year return as of 2026-07-31 close | -46.8% | +181.2% | SION higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.